Evidence mapPaperPMID 40237465Full record

ReviewmBio2025

Parker J Denz, Jacob S Yount

Abstract readReview
In one paragraph

Review in mBio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Parker J DenzDepartment of Microbial Infection and Immunity, The Ohio State University College of Medicine, Columbus, Ohio, USA.ORCID 0000-0001-9420-1337
Jacob S YountDepartment of Microbial Infection and Immunity, The Ohio State University College of Medicine, Columbus, Ohio, USA.ORCID 0000-0002-6128-4575

Funding

Mechanisms of innate resistance to virus infectionsR01AI130110 · NIAID · OHIO STATE UNIVERSITY · 2023 to 2025
$1.3M
Mechanisms of lung and cardiac pathology in SARS-CoV-2 infectionsR01HL168501 · OHIO STATE UNIVERSITY · 2025 to 2025
$717k
Protein therapy to treat virus induced cardiopulmonary injuryR01HL157215 · UNIVERSITY OF VIRGINIA · 2025 to 2025
$655k
NHLBI NIH HHS R01 HL154001NHLBI NIH HHS R01 HL157215NHLBI NIH HHS R01 HL168501NIAID NIH HHS R01 AI130110NIH HHS AI130110, HL168501, HL157215, HL154001
6 · The paper itself

Abstract

Interferon-induced transmembrane protein 3 (IFITM3) is a cellular protein that restricts numerous viral infections by blocking virus-host membrane fusion. In humans, there are two

Indexed as

Membrane ProteinsRNA-Binding ProteinsVirus DiseasesAnimalsCOVID-19HumansInfluenza, HumanMicePolymorphism, Single NucleotideSARS-CoV-2IFITM3 protein, humanMembrane ProteinsRNA-Binding Proteinsemerging virusesIFITM3influenza virusinnate immunitySARS-CoV-2SNP

Identifiers

PMID40237465
PMCPMC12077130

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.